Detectability of HIV residual Viremia despite therapy is highly associated with treatment with a protease inhibitor-based combination antiretroviral therapy
DARCIS, Gilles ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses - médecine interne
MAES, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > Département de gestion des systèmes d'informations (GSI) > Secteur d'appui à la recherche clinique et biostatistique
Pasternak, Alexander
SAUVAGE, Anne-Sophie ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses - médecine interne
FRIPPIAT, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses - médecine interne
MEURIS, Christelle ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses - médecine interne
UURLINGS, Françoise ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Centre de référence VIH/SIDA
LECOMTE, Marianne ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses - médecine interne
LEONARD, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Clinique de médecine des voyageurs
El Moussaoui, Majdouline ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de pneumologie - allergologie
Fombellida, Karine
VAIRA, Dolorès ✱; Centre Hospitalier Universitaire de Liège - CHU > Unilab > Unité de laboratoire - LRS Biomol
MOUTSCHEN, Michel ✱; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service des maladies infectieuses - médecine interne
✱ These authors have contributed equally to this work.
Language :
English
Title :
Detectability of HIV residual Viremia despite therapy is highly associated with treatment with a protease inhibitor-based combination antiretroviral therapy
Publication date :
2019
Journal title :
Antimicrobial Agents and Chemotherapy
ISSN :
0066-4804
eISSN :
1098-6596
Publisher :
American Society for Microbiology, United States - District of Columbia
Deeks SG, Lewin SR, Havlir DV. 2013. The end of AIDS: HIV infection as a chronic disease. Lancet 382:1525–1533. https://doi.org/10.1016/S0140-6736(13)61809-7.
Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, Rimland D, Rodriguez-Barradas MC, Dubrow R, Park LS, Skanderson M, Shiels MS, Gange SJ, Gebo KA, Justice AC, Veterans Aging Cohort Study. 2015. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis 60:627–638. https://doi.org/10.1093/cid/ciu869.
Mitsuyasu RT. 2014. Non-AIDS-defining cancers. Top Antivir Med 22: 660–665.
Deeks SG, Tracy R, Douek DC. 2013. Systemic effects of inflammation on health during chronic HIV infection. Immunity 39:633–645. https://doi.org/10.1016/j.immuni.2013.10.001.
Paiardini M, Muller-Trutwin M. 2013. HIV-associated chronic immune activation. Immunol Rev 254:78–101. https://doi.org/10.1111/imr.12079.
Klatt NR, Chomont N, Douek DC, Deeks SG. 2013. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev 254:326–342. https://doi.org/10.1111/imr.12065.
Douek DC. 2013. Immune activation, HIV persistence, and the cure. Top Antivir Med 21:128–132.
De Voeght A, Martens H, Renard C, Vaira D, Debruche M, Simonet J, Geenen V, Moutschen M, Darcis G. 2017. Exploring the link between innate immune activation and thymic function by measuring sCD14 and TRECs in HIV patients living in Belgium. PLoS One 12:e0185761. https://doi.org/10.1371/journal.pone.0185761.
Massanella M, Fromentin R, Chomont N. 2016. Residual inflammation and viral reservoirs: alliance against an HIV cure. Curr Opin HIV AIDS 11:234–241. https://doi.org/10.1097/COH.0000000000000230.
Cillo AR, Vagratian D, Bedison MA, Anderson EM, Kearney MF, Fyne E, Koontz D, Coffin JM, Piatak M, Jr, Mellors JW. 2014. Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy. J Clin Microbiol 52:3944–3951. https://doi.org/10.1128/JCM.02060-14.
Darcis G, Van Driessche B, Van Lint C. 2017. HIV latency: should we shock or lock? Trends Immunol 38:217–228. https://doi.org/10.1016/j.it.2016.12.003.
Darcis G, Van Driessche B, Bouchat S, Kirchhoff F, Van Lint C. 2018. Molecular control of HIV and SIV latency. Curr Top Microbiol Immunol 417:1–22. https://doi.org/10.1007/82_2017_74.
Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, Beilman GJ, Khoruts A, Thorkelson A, Schmidt TE, Anderson J, Perkey K, Stevenson M, Perelson AS, Douek DC, Haase AT, Schacker TW. 2014. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A 111: 2307–2312. https://doi.org/10.1073/pnas.1318249111.
Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Pond SLK, Chung YS, Penugonda S, Chipman J, Fletcher CV, Schacker TW, Malim MH, Rambaut A, Haase AT, McLean AR, Wolinsky SM. 2016. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 530:51–56. https://doi.org/10.1038/nature16933.
Darcis G, Moutschen M. 2017. The effect of treatment simplification on HIV reservoirs. Lancet HIV 4:e328–e329. https://doi.org/10.1016/S2352-3018(17)30135-2.
Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, Baltimore D. 2011. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477:95–98. https://doi.org/10.1038/nature10347.
Bracq L, Xie M, Benichou S, Bouchet J. 2018. Mechanisms for cell-to-cell transmission of HIV-1. Front Immunol 9:260. https://doi.org/10.3389/fimmu.2018.00260.
Doyle T, Geretti AM. 2012. Low-level viraemia on HAART: significance and management. Curr Opin Infect Dis 25:17–25. https://doi.org/10.1097/QCO.0b013e32834ef5d9.
Reus S, Portilla J, Sanchez-Paya J, Giner L, Frances R, Such J, Boix V, Merino E, Gimeno A. 2013. Low-level HIV viremia is associated with microbial translocation and inflammation. J Acquir Immune Defic Syndr 62:129–134. https://doi.org/10.1097/QAI.0b013e3182745ab0.
Pion M, Jaramillo-Ruiz D, Martínez A, Muñoz-Fernández MA, Correa-Rocha R. 2013. HIV infection of human regulatory T cells downregulates Foxp3 expression by increasing DNMT3b levels and DNA methylation in the FOXP3 gene. AIDS 27:2019–2029. https://doi.org/10.1097/QAD.0b013e32836253fd.
Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, Gatell JM, Domingo P, Paredes R, Sharkey M, Palmer S, Stevenson M, Clotet B, Blanco J, Martinez-Picado J. 2010. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16:460–465. https://doi.org/10.1038/nm.2111.
Hatano H, Strain MC, Scherzer R, Bacchetti P, Wentworth D, Hoh R, Martin JN, McCune JM, Neaton JD, Tracy RP, Hsue PY, Richman DD, Deeks SG. 2013. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis 208: 1436–1442. https://doi.org/10.1093/infdis/jit453.
Haim-Boukobza S, Morand-Joubert L, Flandre P, Valin N, Fourati S, Sayon S, Lavignon M, Simon A, Girard PM, Katlama C, Calvez V, Marcelin AG. 2011. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. AIDS 25:341–344. https://doi.org/10.1097/QAD.0b013e3283427de3.
Pasternak AO, Jurriaans S, Bakker M, Prins JM, Berkhout B, Lukashov VV. 2009. Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One 4:e8490. https://doi.org/10.1371/journal.pone.0008490.
Pasternak AO, de Bruin M, Jurriaans S, Bakker M, Berkhout B, Prins JM, Lukashov VV. 2012. Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis 206:1443–1452. https://doi.org/10.1093/infdis/jis502.
Li JZ, Gallien S, Ribaudo H, Heisey A, Bangsberg DR, Kuritzkes DR. 2014. Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia. AIDS 28:181–186. https://doi.org/10.1097/QAD.0000000000000123.
Yeh RF, Rezk NL, Kashuba AD, Dumond JB, Tappouni HL, Tien HC, Chen YC, Vourvahis M, Horton AL, Fiscus SA, Patterson KB. 2009. Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob Agents Chemother 53:2367–2374. https://doi.org/10.1128/AAC.01523-08.
Bonora S, Nicastri E, Calcagno A, Gonzalez de Requena D, D’Ettorre G, Sarmati L, Palmisano L, Vullo V, Di Perri G, Andreoni M. 2009. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol 81:400–405. https://doi.org/10.1002/jmv.21405.
Lambert-Niclot S, Boyd A, Fofana D, Valin N, Wirden M, Meynard JL, Palich R, Agher R, Valantin MA, Calvez V, Katlama C, Girard PM, Marcelin AG, Morand-Joubert L. 2019. INSTI-based triple regimens in treatment-naive HIV-infected patients are associated with HIV-RNA viral load suppression at ultralow levels. Open Forum Infect Dis 6:ofz177. https://doi.org/10.1093/ofid/ofz177.
Schwartz C, Bouchat S, Marban C, Gautier V, Van Lint C, Rohr O, Le Douce V. 2017. On the way to find a cure: purging latent HIV-1 reservoirs. Biochem Pharmacol 146:10–22. https://doi.org/10.1016/j.bcp.2017.07.001.
Chun TW, Moir S, Fauci AS. 2015. HIV reservoirs as obstacles and opportunities for an HIV cure. Nat Immunol 16:584–589. https://doi.org/10.1038/ni.3152.
Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo Y-R, Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, Barre-Sinoussi F, Alter G, Auerbach J, Autran B, Barouch DH, Behrens G, Cavazzana M, Chen Z, Cohen ÉA, Corbelli GM, Eholié S, Eyal N, Fidler S, Garcia L, Grossman C, Henderson G, Henrich TJ, Jefferys R, Kiem H-P, McCune J, Moodley K, Newman PA, Nijhuis M, Nsubuga MS, Ott M, Palmer S, Richman D, Saez-Cirion A, Sharp M, Siliciano J, Silvestri G, Singh J, Spire B, Taylor J, Tolstrup M, Valente S, van Lunzen J, Walensky R, Wilson I, Zack J. 2016. International AIDS Society global scientific strategy: towards an HIV cure, 2016. Nat Med 22: 839 – 850. https://doi.org/10.1038/nm.4108.
Gianotti N, Galli L, Galizzi N, Ripa M, Andolina A, Nozza S, Spagnuolo V, Poli A, Lazzarin A, Castagna A. 2018. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen. Int J Antimicrob Agents 52: 492–499. https://doi.org/10.1016/j.ijantimicag.2018.07.001.
Moron-Lopez S, Navarro J, Jimenez M, Rutsaert S, Urrea V, Puertas MC, Torrella A, Clercq L, Ribas BP, Galvez C, Salgado M, Vandekerckhove L, Blanco J, Crespo M, Martinez-Picado J. 2018. Switching from a protease inhibitor-based regimen to a dolutegravir-based regimen: a randomized clinical trial to determine the effect on peripheral blood and ileum biopsies from ART-suppressed HIV-infected individuals. Clin Infect Dis https://doi.org/10.1093/cid/ciy1095.
Pasternak AO, de Bruin M, Bakker M, Berkhout B, Prins JM. 2015. High current CD4+ T cell count predicts suboptimal adherence to antiretroviral therapy. PLoS One 10:e0140791. https://doi.org/10.1371/journal.pone.0140791.
Fourati S, Flandre P, Calin R, Carcelain G, Soulie C, Lambert-Niclot S, Maiga A, Ait-Arkoub Z, Tubiana R, Valantin MA, Autran B, Katlama C, Calvez V, Marcelin AG. 2014. Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy. J Antimicrob Chemother 69:753–756. https://doi.org/10.1093/jac/dkt428.
Lambert-Niclot S, Flandre P, Valantin MA, Soulie C, Fourati S, Wirden M, Sayon S, Pakianather S, Bocket L, Masquelier B, Dos Santos G, Katlama C, Calvez V, Marcelin AG. 2012. Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOIANRS136 trial over 96 weeks. PLoS One 7:e41390. https://doi.org/10.1371/journal.pone.0041390.
Burgard M, Boufassa F, Viard JP, Garrigue I, Ruffault A, Izopet J, Vabret A, Descamps D, Colson P, Seigneurin JM, Rouzioux C, Group A. 2009. Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients. AIDS 23:2165–2171. https://doi.org/10.1097/QAD.0b013e32833032d4.
Buzon MJ, Martin-Gayo E, Pereyra F, Ouyang Z, Sun H, Li JZ, Piovoso M, Shaw A, Dalmau J, Zangger N, Martinez-Picado J, Zurakowski R, Yu XG, Telenti A, Walker BD, Rosenberg ES, Lichterfeld M. 2014. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol 88:10056–10065. https://doi.org/10.1128/JVI.01046-14.
Cuzin L, Pugliese P, Saune K, Allavena C, Ghosn J, Cottalorda J, Rodallec A, Chaix ML, Fafi-Kremer S, Soulie C, Ouka M, Charpentier C, Bocket L, Mirand A, Guiguet M, Asg D. 2015. Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy. AIDS 29:1665–1671. https://doi.org/10.1097/QAD.0000000000000723.
Avettand-Fenoel V, Hocqueloux L, Ghosn J, Cheret A, Frange P, Melard A, Viard JP, Rouzioux C. 2016. Total HIV-1 DNA, a marker of viral reservoir dynamics with clinical implications. Clin Microbiol Rev 29:859 – 880. https://doi.org/10.1128/CMR.00015-16.
Trejbalová K, Kovářová D, Blažková J, Machala L, Jilich D, Weber J, Kučerová D, Vencálek O, Hirsch I, Hejnar J. 2016. Development of 5= LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals. Clin Epigenetics 8:19. https://doi.org/10.1186/s13148-016-0185-6.
Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, Owen A, Phillips AN, Geretti AM. 2012. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 54:724–732. https://doi.org/10.1093/cid/cir936.
University of Bern. 2009. The STROBE statement. University of Bern, Bern, Switzerland. https://www.strobe-statement.org/index.php?id=strobe-home.
